Elena Peeva, M.D., M.Sc., Gisele Zandman-Goddard, M.D., and Peter Barland, M.D.

Dr. Peeva is Instructor of Medicine at the Albert Einstein College of Medicine and Attending Physician at Montefiore Medical Center, New York; Dr. Zandman-Goddard is Instructor of Medicine and Attending Physician at Sheba Medical Center, Israel.Drs. Peeva, Zandman-Goddard and Barland report no commercial conflicts of interest.

Release Date: 03/01/2001
Termination Date: 03/01/2004

Estimated time to complete: 1 hour(s).

Albert Einstein College of Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Albert Einstein College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Upon completion of this Cyberounds^®, the participant should be able to:

• Describe the mechanism of action and major side effects of the new cytotoxic agents used in treatment of SLE: MMF, fludarabine and cladribine
• Discuss induction of B cell tolerance by LJP 394
• Describe the stem cell restoration treatment and the mechanism of action and effects of intravenous immunoglobulin
• Describe the mechanism of action of targeted molecular therapies.

 

This conference may include discussion of commercial products and services.

The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor or its publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.

 

Please click below to accept the terms of this CME activity